Get the latest Science News and Discoveries

LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate

None

Get the Android app

Or read this on Eureka Alert

« TALENT study supports NLCST and NELSON trial results

Selected gene mRNA expression is not predictive of improved overall survival »